-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

ASH Poster Walk on Geriatric Hematology: Selecting the Right Treatment for the Patient, Not Just the Disease

Program: ASH Poster Walks
Hematology Disease Topics & Pathways:
Clinical Trials, Biological therapies, Epidemiology, Non-Biological therapies, Age Inequities, Workforce, Health Outcomes Research, Elderly, Health Disparities Research, Diversity, Equity, Inclusion, and Accessibility (DEI/DEIA) , Patient-Reported Outcomes, Real World Evidence, Therapies, Registries, Adverse Events, Study Population, Diversity, Equity, and Inclusion (DEI), Clinical Practice (e.g. Guidelines, Health Outcomes and Services, and Survivorship, Value; etc.)
Wednesday, December 15, 2021: 5:00 PM-6:00 PM
(VIRTUAL PROGRAM)
Please view the recorded poster presentations prior to attending this virtual session:

Abstracts incorporating the principles of geriatrics into research and clinical practice of caring for older adults with hematologic conditions (both malignant and nonmalignant) are of increasing interest to ASH participants. The ASH Poster Walk on Geriatric Hematology will aggregate these diverse abstracts into a single discussion, allowing key opinion leaders to provide context on the current state of the art in geriatric hematology, covering topics including elderly-specific therapeutic trials, frailty and geriatric assessment.

The following abstracts will be featured in this session:

Final Induction Therapy Results of an Open Label Phase II Study Using Inotuzumab Ozogamicin for Induction Therapy, Followed By a Conventional Chemotherapy Based Consolidation and Maintenance Therapy in Patients Aged 56 Years and Older with Acute B-Lymphoblastic Leukemia (INITIAL-1 trial), Matthias Stellijes

Emicizumab Prophylaxis in Persons with Hemophilia A, Aged ≥50 Years, with Comorbidities – Pooled Data from Four Phase III Studies (HAVEN 1, 3, and 4, and STASEY), Victor Jimenez-Yuste

The Prognostic Implication of Adult Comorbidity Evaluation 27 Score in CML Patients on Tyrosine-Kinase Inhibitors, Kunhwa Kim

Isatuximab Rescue for Inadequate Response to Lenalidomide and Dexamethasone in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma: Interim Analysis of the Phase II Iril Study of the Australian Myeloma Research Consortium (AMaRC 18-02), Slavisa Ninkovic

Development and Testing of a Lymphoma Clinical Trials Specific Frailty Index: A Secondary Analysis of the LY.12 Clinical Trial, Abi Vijenthira

A Cross-Sectional Analysis of County-Level Social Vulnerability and Physical Frailty Among Adults with Hematological Malignancies, Shakira Grant

See more of: ASH Poster Walks